Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2024-01-03 00:00:00 ET · period of report 2023-12-31 · accession 0001610717-24-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-03 | 2023-12-31 | CHRS | Stilwell McDavid | CFO | F - Tax | $3.33 | -18.4K | 75.3K | -20% | -$61.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-31 | F | D | 18,440 | $3.33 | 75,305 | D | — | — | (F1) Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. (F2) Includes 4,826 shares acquired on November 15, 2023, pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan and includes the cancellation of 13,333 restricted stock units. |